BLEPHAMIDE S.O.P. Drug Patent Profile
✉ Email this page to a colleague
When do Blephamide S.o.p. patents expire, and what generic alternatives are available?
Blephamide S.o.p. is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in BLEPHAMIDE S.O.P. is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BLEPHAMIDE S.O.P.?
- What are the global sales for BLEPHAMIDE S.O.P.?
- What is Average Wholesale Price for BLEPHAMIDE S.O.P.?
Summary for BLEPHAMIDE S.O.P.
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Clinical Trials: | 1 |
| Patent Applications: | 28 |
| DailyMed Link: | BLEPHAMIDE S.O.P. at DailyMed |
Recent Clinical Trials for BLEPHAMIDE S.O.P.
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Massachusetts Eye and Ear Infirmary | Phase 4 |
| Joseph B. Ciolino, MD | Phase 4 |
US Patents and Regulatory Information for BLEPHAMIDE S.O.P.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | BLEPHAMIDE S.O.P. | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 087748-001 | Dec 3, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
